Published by Global Banking & Finance Review®
Posted on July 22, 2025
1 min readLast updated: January 22, 2026
Add as preferred source on GoogleCapVest Partners is in talks to acquire a majority stake in Stada Arzneimittel for €10 billion, including debt. The deal involves discussions with Bain Capital and Cinven.
(Reuters) -London-based buyout firm CapVest Partners is in talks to acquire a majority stake in German drugmaker Stada Arzneimittel, Bloomberg News reported on Tuesday.
The deal would value Stada Arzneimittel at about 10 billion euros ($11.75 billion) including debt, the report said, citing unnamed sources.
CapVest is in discussions with Stada's private equity owners, Bain Capital and Cinven, regarding the transaction. Stada has also been exploring a potential listing, the report said.
CapVest declined comment, while Stada did not immediately respond to a Reuters' request for comment.
Stada, known for its cold medicine Grippostad, sunscreen Ladival and the cough syrup Silomat in March, postponed a planned IPO in Frankfurt due to market volatility.
Bankers advising Bain Capital and Cinven recommended against proceeding with the listing at that time, Reuters reported.
($1 = 0.8511 euros)
(Reporting by Angela Christy in Bengaluru; Editing by Tasim Zahid)
The deal would value Stada Arzneimittel at about 10 billion euros ($11.75 billion) including debt.
Stada is currently owned by private equity firms Bain Capital and Cinven.
Stada postponed its planned IPO in Frankfurt due to market volatility, as advised by bankers.
Stada is known for products such as the cold medicine Grippostad, sunscreen Ladival, and the cough syrup Silomat.
CapVest declined to comment on the acquisition discussions, while Stada did not immediately respond to requests for comment.
Explore more articles in the Headlines category
